Akers Biosciences, Inc. Issue of Equity (0604C)
10 April 2017 - 9:00PM
UK Regulatory
TIDMAKR
RNS Number : 0604C
Akers Biosciences, Inc.
10 April 2017
April 10, 2017
Akers Biosciences, Inc.
Issue of Equity
Further to the announcement of April 6, 2017 concerning the
conversion of a further 3,300 warrants in the Company, Akers
Biosciences, Inc. (NASDAQ: AKER) (AIM: AKR.L), (the "Company" or
"Akers Bio"), a developer of rapid health information technologies,
announces that it will apply for the admission of the 3,300 common
shares to AIM and this is expected to take place on April 18, 2017
("Admission"). Following Admission, the Company's issued share
capital will consist of 8,853,745 common shares with no common
shares held in treasury. Therefore, the above figure of 8,853,745
may be used by shareholders as the denominator for the calculations
by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the FCA's Disclosure and Transparency Rules.
About Akers Biosciences, Inc.
Akers Bio develops, manufactures, and supplies rapid screening
and testing products designed to deliver quicker and more
cost-effective healthcare information to healthcare providers and
consumers. The Company has advanced the science of diagnostics
while responding to major shifts in healthcare through the
development of several proprietary platform technologies. The
Company's state-of-the-art rapid diagnostic assays can be performed
virtually anywhere in minutes when time is of the essence. The
Company has aligned with major healthcare companies and high volume
medical product distributors to maximize product offerings, and to
be a major worldwide competitor in diagnostics.
Additional information on the Company and its products can be
found at www.akersbio.com. Follow us on Twitter @AkersBio.
Cautionary Statement Regarding Forward Looking Statements
Statements contained herein that are not based upon current or
historical fact are forward-looking in nature and constitute
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933 and Section 21E of the Securities Exchange
Act of 1934. Such forward-looking statements reflect the Company's
expectations about its future operating results, performance and
opportunities that involve substantial risks and uncertainties.
These statements include but are not limited to statements
regarding the intended terms of the offering, closing of the
offering and use of any proceeds from the offering. When used
herein, the words "anticipate," "believe," "estimate," "upcoming,"
"plan," "target", "intend" and "expect" and similar expressions, as
they relate to Akers Biosciences, Inc., its subsidiaries, or its
management, are intended to identify such forward-looking
statements. These forward-looking statements are based on
information currently available to the Company and are subject to a
number of risks, uncertainties, and other factors that could cause
the Company's actual results, performance, prospects, and
opportunities to differ materially from those expressed in, or
implied by, these forward-looking statements.
For more information:
Akers Biosciences, Inc.
John J. Gormally, Chief Executive Officer
Raymond F. Akers, Jr. PhD, Vice Chairman
Tel. +1 856 848 8698
finnCap (UK Nominated Adviser and Broker)
Adrian Hargrave / Scott Mathieson (Corporate Finance)
Steve Norcross (Broking)
Tel. +44 (0)20 7220 0500
Vigo Communications (Global Public Relations)
Ben Simons / Fiona Henson
Tel. +44 (0)20 7830 9704
Email: akers@vigocomms.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEOKKDKKBKDQQD
(END) Dow Jones Newswires
April 10, 2017 07:00 ET (11:00 GMT)
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From Apr 2024 to May 2024
Akers Biosciences (LSE:AKR)
Historical Stock Chart
From May 2023 to May 2024